help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GREATENS, T. M.
Right arrow Articles by NIEWOEHNER, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GREATENS, T. M.
Right arrow Articles by NIEWOEHNER, D. E.

Am. J. Respir. Crit. Care Med., Volume 157, Number 4, April 1998, 1093-1097

Do Molecular Markers Predict Survival in Non-Small-Cell Lung Cancer?

TODD M. GREATENS, GLORIA A. NIEHANS, JEFFREY B. RUBINS, JOSE JESSURUN, ROBERT A. KRATZKE, MICHAEL A. MADDAUS, and DENNIS E. NIEWOEHNER

Departments of Medicine, Pathology, and Surgery, Veterans Affairs Medical Center, and the University of Minnesota Medical School, Minneapolis, Minnesota

Patients with non-small-cell lung cancer (NSCLC) survive for variable lengths of time, even when adjustment is made for pathological stage. Numerous reports suggest that biological markers predict survival in patients undergoing surgery for NSCLC with curative intent, but many of these claims are unconfirmed or conflicting. We postulated that the use of multiple putative markers might provide greater power in predicting survival. We studied 101 consecutive patients with NSCLC who underwent exploratory thoracotomy and who were followed for at least 2 yr. We assessed mutations in the p53 tumor suppressor gene (exons 5-8) and the K-ras oncogene (codons 12 and 13) by polymerase chain reaction amplification and single strand conformation polymorphism of the product. We identified 19 K-ras mutations (all adenocarcinomas except for two) and 40 p53 mutations among the 101 cases. We also evaluated p53 protein, bcl-2 protein, c-erbB-1 protein, c-erbB-2 protein, and MIA-15-5 antigen by standard immunocytochemical techniques, and we found that all of these antigens were variably expressed. As expected, we found a strong inverse association between surgical tumor stage and survival. Of the molecular markers studied, only MIA-15-5 antigen expression correlated strongly with survival by univariate analysis (p = 0.001) and it remained a significant predictor by multivariate analysis (p = 0.01). However, in this study, overexpression of MIA-15-5 antigen predicted an improved survival, whereas the original report showed a worse prognosis (N. Engl. J. Med. 1992;327:14). We conclude the multiple cell markers are not clinically useful in predicting survival among patients undergoing surgery for NSCLC. Differences between our results and prior reports may be due to chance, to true population differences, or to other factors.




This article has been cited by other articles:


Home page
 The OncologistHome page
R. S. Herbst and A. Sandler
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Oncologist, November 1, 2008; 13(11): 1166 - 1176.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Lynch Jr., E. S. Kim, B. Eaby, J. Garey, D. P. West, and M. E. Lacouture
Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
Oncologist, May 1, 2007; 12(5): 610 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
C. Gebitekin, A. S Bayram, B. Tunca, and S. A Balaban
Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer
Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 35 - 38.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Nakamura, N Kawasaki, M Taguchi, and K Kabasawa
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Thorax, February 1, 2006; 61(2): 140 - 145.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Thomas, L. A. Doyle, and M. J. Edelman
Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy
Chest, July 1, 2005; 128(1): 370 - 381.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Chest, March 1, 2005; 127(3): 978 - 983.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gurubhagavatula, G. Liu, S. Park, W. Zhou, L. Su, J. C. Wain, T. J. Lynch, D. S. Neuberg, and D. C. Christiani
XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non--Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy
J. Clin. Oncol., July 1, 2004; 22(13): 2594 - 2601.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr, M. V. Di Maria, R. Veve, R. M. Bremnes, A. E. Baron, C. Zeng, and W. A. Franklin
Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis
J. Clin. Oncol., October 15, 2003; 21(20): 3798 - 3807.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
W Hilbe, S Dirnhofer, F Oberwasserlechner, W Eisterer, K Ammann, T Schmid, G Hilbe, J Thaler, and E Woll
Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis
J. Clin. Pathol., October 1, 2003; 56(10): 736 - 741.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
Y.-L. Cheng, S.-C. Lee, H.-J. Harn, C.-J. Chen, Y.-C. Chang, J.-C. Chen, and C.-P. Yu
Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer
Eur. J. Cardiothorac. Surg., February 1, 2003; 23(2): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
Eur. Respir. J., October 1, 2002; 20(4): 975 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
R.-S. Lai, J.-S. Wang, H.-K. Hsu, H.-C. Chang, C.-H. Lin, and M.-H. Lin
Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Resected Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., October 1, 2002; 32(10): 393 - 397.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Marchetti, N. Tinari, F. Buttitta, A. Chella, C. A. Angeletti, R. Sacco, F. Mucilli, A. Ullrich, and S. Iacobelli
Expression of 90K (Mac-2 BP) Correlates with Distant Metastasis and Predicts Survival in Stage I Non-Small Cell Lung Cancer Patients
Cancer Res., May 1, 2002; 62(9): 2535 - 2539.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Bepler, A. Gautam, L. M. McIntyre, A. F. Beck, D. S. Chervinsky, Y.-C. Kim, D. M. Pitterle, and A. Hyland
Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1353 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. D'Cunha, A. L. Corfits, J. E. Herndon II, J. A. Kern, L. J. Kohman, G. A. Patterson, R. A. Kratzke, and M. A. Maddaus
Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of cancer and leukemia group B trial 9761
J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 484 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Gessner, U. Liebers, H. Kuhn, P. Stiehl, C. Witt, J. Schauer, and G. Wolff
BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer
Eur. Respir. J., January 1, 2002; 19(1): 134 - 140.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Ramnath, F. J. Hernandez, D.-F. Tan, J. A. Huberman, N. Natarajan, A. F. Beck, A. Hyland, I. T. Todorov, J. S.J. Brooks, and G. Bepler
MCM2 Is an Independent Predictor of Survival in Patients With Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 15, 2001; 19(22): 4259 - 4266.
[Abstract] [Full Text]

Home page
 Eur Respir JHome page
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
Eur. Respir. J., October 1, 2001; 18(4): 705 - 719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Moldvay, P. Scheid, P. Wild, K. Nabil, J. Siat, J. Borrelly, B. Marie, G. Farré, T. Labib, G. Pottier, et al.
Predictive Survival Markers in Patients with Surgically Resected Non-Small Cell Lung Carcinoma
Clin. Cancer Res., March 1, 2000; 6(3): 1125 - 1134.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
I. Murakami, K. Hiyama, S. Ishioka, M. Yamakido, F. Kasagi, and Y. Yokosaki
p53 Gene Mutations Are Associated with Shortened Survival in Patients with Advanced Non-small Cell Lung Cancer: An Analysis of Medically Managed Patients
Clin. Cancer Res., February 1, 2000; 6(2): 526 - 530.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
H. H. Nelson, D. C. Christiani, E. J. Mark, J. K. Wiencke, J. C. Wain, and K. T. Kelsey
Implications and Prognostic Value of K-ras Mutation for Early-Stage Lung Cancer in Women
J Natl Cancer Inst, December 1, 1999; 91(23): 2032 - 2038.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. B. Rubins, J. Dunitz, H. B. Rubins, M. A. Maddaus, and D. E. Niewoehner
Serum carcinoembryonic antigen as an adjunct to preoperative stagingof lung cancer
J. Thorac. Cardiovasc. Surg., September 1, 1998; 116(3): 412 - 416.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  ATS PAR News